1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
China National Accord Medicines Corporation Ltd Class A

China National Accord Medicines Corporation Ltd Class A

12.32
HKD
+0.03
(+0.24%)
14.05BMarket Cap
Apr 14Next Earn
China National Accord Medicines Corporation Ltd Class A
SZSE:200028
(Shenzhen Stock Exchange)

Recent

price

12.32

P/E

ratio

- -

div

yld

5.84%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
16.2
18.72
22.23
26.24
24.82
31.78
34.64
34.29
35.87
43.86
49.52
56.8
61.02
62.67
61.59
61
- -
Revenue per Share
0.32
0.41
0.59
0.64
0.68
0.78
1
0.88
1.01
1.05
1.16
1.11
1.24
1.33
0.53
0.94
- -
Basic EPS, GAAP
0.31
0.04
0.16
0.39
-1.18
0.97
1.01
0.9
0.89
1.46
1
1.07
1.86
2.17
2.48
1.18
- -
Free Cash Flow per Basic Share
0.13
0.17
0.23
0.27
0.22
0.19
0.18
0.2
0.23
0.41
0.46
0.51
0.48
0.46
0.5
0.32
0.62
Dividend per Share
1.3
1.67
2.19
2.77
4.68
7.22
8.3
7.81
9.66
10.73
11.59
12.41
13.41
14.48
14.69
15.47
15.69
Book Value per Share
1.07
1.45
1.89
2.47
4.45
6
7.17
6.85
8.7
9.58
8.7
9.54
10.58
11.68
12.74
13.8
14.03
Tangible Book Value per Share
806
809
810
808
965
1,190
1,191
1,203
1,202
1,204
1,205
1,204
1,204
1,204
1,208
1,204
758
Basic Weighted Avg Shares
13,064
15,150
18,012
21,199
23,954
37,819
41,248
41,263
43,122
52,787
59,649
68,358
73,443
75,477
74,378
73,416
- -
Sales/Revenue/Turnover
2.97
3.4
3.98
3.82
3.79
3.61
3.44
3.17
3.38
3.34
3.39
3.15
3.28
3.31
2.25
2.51
- -
Operating Margin (%)
83
90
95
99
105
168
166
108
116
819
1,058
1,268
1,307
1,426
1,545
1,261
- -
Depreciation Expense
261
328
476
520
652
928
1,187
1,058
1,211
1,268
1,402
1,336
1,487
1,599
642
1,136
- -
Net Income, GAAP
22.24
20
19.83
18.95
19.23
20.62
19.9
21.1
19.69
20.05
20.21
22.65
23.34
20.81
58.82
25.23
- -
Effective Tax Rate (%)
2
2.17
2.64
2.46
2.72
2.45
2.88
2.56
2.81
2.4
2.35
1.96
2.02
2.12
0.86
1.55
- -
Profit Margin (%)
207
442
734
979
3,304
4,730
5,553
6,191
9,738
9,932
9,005
9,469
10,681
12,032
12,774
14,091
14,485
Working Capital
30
93
82
- -
40
72
15
32
32
1,208
1,335
1,447
1,345
1,452
1,371
912
833
LT Debt
1,131
1,427
1,839
2,317
4,851
7,872
8,918
9,928
13,906
15,574
16,889
18,022
19,445
20,978
20,755
21,624
21,894
Total Equity
12.37
11.07
12.84
11.84
10.9
12.13
12.28
10.35
9.43
8.17
8.66
6.98
7.74
7.9
0.9
4.36
- -
Return on Invested Capital (%)
15.81
15.77
16.81
14.96
13.22
11.5
11.94
9.69
8.76
7.19
6.54
6.39
6.2
5.86
4.43
4.96
- -
Return on Capital (%)
27.49
27.33
30.44
25.89
18.62
15.31
15.01
11.85
11.52
10.34
10.44
9.26
9.58
9.54
3.66
6.26
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,343
3,233
2,519
LT Borrowings
- -
- -
- -
LT Finance Leases
912
862
833
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,203
1,203
1,203
Market Capitalization
13,119
13,165
12,157

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
40,196
40,308
39,489
Cash, Cash Equivalents & STI
7,802
5,179
5,933
Accounts Receivable, Net
21,538
23,899
22,771
Inventories
8,122
8,474
8,158
Total Current Liabilities
26,105
25,898
25,004
Payables & Accruals
- -
- -
- -
ST Debt
3,343
3,233
2,519
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.07%
5.12%
4.19%
Free Cash Flow
8.54%
11.83%
-52.45%
Net Income, GAAP
7.79%
6.22%
76.8%
Sales/Revenue/Turnover
7.11%
4.41%
-1.29%
Total Cash Common Dividend
8.88%
-5.12%
-36.02%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19,090
18,695
18,680
17,912
74,378
2025
18,294
18,503
- -
18,291
73,416
2026
17,823
18,443
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.32
0.58
0.53
-0.69
0.53
2025
0.27
0.55
- -
0.29
0.94
2026
0.24
0.52
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.69
0.11
0.09
0.5
2025
0.04
0.41
- -
0.07
0.32
2026
0.03
0.64
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
China National Accord Medicines Corporation Ltd. (000028.SZ) engages in the wholesale distribution, retail, and related services for pharmaceutical and healthcare products primarily in China. The company offers drugs including proprietary Chinese medicines, chemical preparations, antibiotics, biochemical drugs, biological preparations, and diagnostic drugs; medical equipment and devices; health supplies, cosmetics, and daily necessities; cargo transportation, warehousing, loading and unloading, glass instruments, agent services, professional consulting, and house leasing; as well as import and export of therapeutic biological products, packaged foods, chemical products, house supplies, and self-operated technologies. It operates through pharmaceutical distribution focused on Guangdong and Guangxi regions with coverage of over 17,000 customers including hospitals, primary medical institutions, and retail terminals; pharmaceutical retail via its Guoda Drugstore subsidiary with approximately 7,660 stores across 20 provinces, municipalities, and autonomous regions; and industrial investments. As a subsidiary of Sinopharm Group Co., Ltd., it maintains a nationwide network with large-scale logistics centers in key cities, serving medical institutions, chain pharmacies, and consumers. Founded in 1993 and headquartered in Shenzhen, China, the company previously operated as Shenzhen Health Mineral Water Corp., Ltd. Recent developments include Guoda Drugstore's acquisitions of Chengda Fangyuan Pharmaceutical Group Co., Ltd. and Shanghai Dingqun Enterprise Management Consulting Co., Ltd. in 2020, adding over 1,500 stores and boosting retail scale; expansion of its own-brand portfolio with mid-to-high-end nutrient series through partnerships with Sinopharm affiliates like Sinopharm Medical Device and China TCM; and ongoing integration of wholesale and retail operations in 15 regions, alongside digital transformation for supply chain efficiency. In 2025, it reported earnings for periods ended March, June, and September, with dividends declared for 2024, reflecting continued focus on profitability amid market challenges.